Gemvax&Kael announced their full-scale entry into the pharmaceutical industry through the acquisition of Samsung Pharmaceutical
On May 22, Gemvax&Kael announced their full-scale entry into the pharmaceutical industry through the acquisition of Samsung Pharmaceutical Industry which is listed on the securities market. Gemvax&Kael is a parent company of Kaelgemvax which is developing the world's first anti-cancer vaccine for...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
